CClinicalTrials.gg
CompletedNCT00341952Updated Nov 27, 2020

Interdisciplinary Case-Control Study of Non-Hodgkin's Lymphoma

An observational study in Non-Hodgkin's Lymphoma, sponsored by National Cancer Institute (NCI). Completed at 4 sites in United States. Open to participants aged 20 Years to 74 Years. Per ClinicalTrials.gov, last updated 2020-11-27.

Sponsored by National Cancer Institute (NCI) · Observational

Study type
Observational
Model
Case-control
Time perspective
Retrospective
Enrollment
2,378
Ages
20 Years to 74 Years
Sex
All
01

Study summary

Non-Hodgkin's lymphoma (NHL) incidence rates have risen three percent per year in the U.S. for four decades. Mortality from NHL has risen 1.6 percent, compared with 0.2 percent for all cancers combined. This epidemic curve appears in both sexes and around the world, suggesting the possibility of an etiologic agent increasing in prevalence in the general environment. Recent research has identified several possible candidates including pesticides, other organochlorines, drinking water nitrates, and sunlight. There is an urgent need to evaluate whether these common exposures are contributing to the rapid rise in NHL, and to investigate other hypothesized risk factors such as viruses, medical conditions, hair dye use, and genetic factors. The purpose of this study is to examine the contribution to NHL risk of these important environmental, occupational, viral, medical, and personal exposures, and to pursue important leads emerging from on-going NHL research. This multidisciplinary, population-based case-control study will involve personal interviews to collect information on demographics, residential history, pesticide use, and occupational exposures; self-administered questionnaires to collect information on diet, family and medical history, and other exposures; tap water and carpet dust sampling to collect information on nitrate and pesticide exposures; and blood sampling for measurements of compounds in the serum, antibodies to viruses, and examination of genetic polymorphisms.

Read the detailed description

Non-Hodgkin's lymphoma (NHL) incidence rates have risen three percent per year in the U.S. for four decades. Mortality from NHL has risen 1.6 percent, compared with 0.2 percent for all cancers combined. This epidemic curve appears in both sexes and around the world, suggesting the possibility of an etiologic agent increasing in prevalence in the general environment. Recent research has identified several possible candidates including pesticides, other organochlorines, drinking water nitrates, and sunlight. There is an urgent need to evaluate whether these common exposures are contributing to the rapid rise in NHL, and to investigate other hypothesized risk factors such as viruses, medical conditions, hair dye use, and genetic factors. The purpose of this study is to examine the contribution to NHL risk of these important environmental, occupational, viral, medical, and personal exposures, and to pursue important leads emerging from on-going NHL research. This multidisciplinary, population-based case-control study will involve personal interviews to collect information on demographics, residential history, pesticide use, and occupational exposures; self-administered questionnaires to collect information on diet, family and medical history, and other exposures; tap water and carpet dust sampling to collect information on nitrate and pesticide exposures; and blood sampling for measurements of compounds in the serum, antibodies to viruses, and examination of genetic polymorphisms.

02

Conditions studied

  • Non-Hodgkin's Lymphoma

Keywords

  • Case-Control Study
  • Non-Hodgkin Lymphoma
03

In context

Lymphoma

5,578 studies on the registry are indexed under Lymphoma; 825 are open to participants now.

This study's enrollment of 2,378 is above the median of 136 across 625 observational studies indexed under Lymphoma.

Browse Lymphoma studies →

Lead sponsor

National Cancer Institute (NCI) is the lead sponsor of 3,506 studies on the registry; 334 are open to participants now.

Of its 402 completed or terminated interventional studies of FDA-regulated products, 365 (91%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Residents of participating SEER registries

Eligibility criteria

  • ELIGIBILITY CRITERIA:

Women and men residing in the areas served by the four SEER registries.

Individuals between the ages of 20 and 74 (ages between 20 and 64 must live in households with telephones).

Individuals who have a first primary diagnosis of NHL after April 1, 1998 to July 1, 1998.

Individuals must be HIV negative.

EXCLUSION CRITERIA:

Individuals must not be previously diagnosed with NHL.

05

Study design

Observational model
Case-control
Time perspective
Retrospective
Enrollment
2,378 participants (actual)

Groups and cohorts

  • Cases

    individuals diagnosed with incident, first primary non-Hodgkin lymphoma

  • Controls

    individuals identified in the same geographical areas without non-Hodgkin lymphoma or othercancers

06

What researchers measure

Primary outcomes

  1. No intervention. Observational study compares cases and controls.

    non-Hodgkin lymphoma cases versus controls

    Time frame: at the time of enrollment

07

Study locations

4 sites
  • University of Southern California
    Los Angeles, California 90033, United States
  • University of Iowa
    Iowa City, Iowa 52242, United States
  • Wayne State University Hutzel Hospital
    Detroit, Michigan 48201, United States
  • University of Washington
    Seattle, Washington 98195, United States
08

References and documents

Publications

  • Gridley G, McLaughlin JK, Ekbom A, Klareskog L, Adami HO, Hacker DG, Hoover R, Fraumeni JF Jr. Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst. 1993 Feb 17;85(4):307-11. doi: 10.1093/jnci/85.4.307. PubMed 8426374 ↗
  • Cantor KP, Blair A, Everett G, VanLier S, Burmeister L, Dick FR, Gibson RW, Schuman L. Hair dye use and risk of leukemia and lymphoma. Am J Public Health. 1988 May;78(5):570-1. doi: 10.2105/ajph.78.5.570. PubMed 3354743 ↗
  • Bentham G. Association between incidence of non-Hodgkin's lymphoma and solar ultraviolet radiation in England and Wales. BMJ. 1996 May 4;312(7039):1128-31. doi: 10.1136/bmj.312.7039.1128. PubMed 8620128 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 27, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00341952
Lead sponsor
National Cancer Institute (NCI)
Responsible party
Sponsor
First posted
Jun 21, 2006
Start date
Apr 15, 1998
Primary completion
Apr 17, 2007
Completion
Apr 17, 2007
Last update
Nov 27, 2020

Study contacts

Nathaniel Rothman, M.D.
principal investigator · National Cancer Institute (NCI)
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion